Nonmalignant brain tumors are underreported by an estimated 60% in Canadian cancer registries. One explanation is that radiology facilities or their databases may not be adequately included in the cancer reporting infrastructure. A multidisciplinary stakeholder team met for 1 day, followed by teleconferences, to discuss the evidence for the importance of incorporating radiology diagnoses in brain tumor reports. A role for the neuroradiologist was delineated in brain tumor diagnosis and in ensuring that radiology report information is available to support cancer case ascertainment in the cancer surveillance system. It was noted that brain tumors identified through imaging are clinically managed depending on the diagnosis and prognosis of the disease, and that patient radiology reports become a part of a larger administrative information system. The proportion of nonmalignant brain tumors diagnosed using histology is lower in the United States (49.3%) than in Canada (59%), suggesting that a higher proportion of cases with nonhistologic (likely radiology) diagnosis are captured by the US system (eg, tumors of the sellar region, cranial and spinal tumors, and tumors of the meninges). Finding a way to use existing electronic radiology reports to identify nonmalignant brain tumors needs to be prioritized. This will require access to electronic radiology reports, as manual reporting is impractical. Once access is achieved, an electronic flag to identify new cases through a natural language processing algorithm could be pursued. As radiologists and cancer registrars become more familiar with each other's mandates and workflow demands, innovative and collaborative solutions to improve case ascertainment for brain and other cancers are likely to emerge.
Download full-text PDF |
Source |
---|
CNS Neurosci Ther
January 2025
Jiujiang Clinical Precision Medicine Research Center, Jiujiang, Jiangxi, China.
Background: Adenosine deaminase action on RNA 1 (ADAR1) can convert the adenosine in double-stranded RNA (dsRNA) molecules into inosine in a process known as A-to-I RNA editing. ADAR1 regulates gene expression output by interacting with RNA and other proteins; plays important roles in development, including growth; and is linked to innate immunity, tumors, and central nervous system (CNS) diseases.
Results: In recent years, the role of ADAR1 in tumors has been widely discussed, but its role in CNS diseases has not been reviewed.
Sci Rep
January 2025
Department of Electronics, Information and Communication Engineering, Kangwon National University, Samcheok, Republic of Korea.
Detecting brain tumours (BT) early improves treatment possibilities and increases patient survival rates. Magnetic resonance imaging (MRI) scanning offers more comprehensive information, such as better contrast and clarity, than any alternative scanning process. Manually separating BTs from several MRI images gathered in medical practice for cancer analysis is challenging and time-consuming.
View Article and Find Full Text PDFNPJ Precis Oncol
January 2025
Athinoula A. Martinos Center for Biomedical Imaging, 149 13th St, Charlestown, MA, 02129, USA.
Recent progress in deep learning (DL) is producing a new generation of tools across numerous clinical applications. Within the analysis of brain tumors in magnetic resonance imaging, DL finds applications in tumor segmentation, quantification, and classification. It facilitates objective and reproducible measurements crucial for diagnosis, treatment planning, and disease monitoring.
View Article and Find Full Text PDFObjectives: To explore the impact of the SARS-CoV-2/COVID-19 pandemic on the diagnosis, management and patient journey for children and young people with a newly diagnosed brain tumour in the UK.
Design: Exploratory qualitative study focused on patient journeys from multiple perspectives, conducted as part of a wider mixed-methods study.
Setting: Three paediatric oncology tertiary centres in the UK.
Cancer Cell
December 2024
National Health Commission Key Laboratory of Antibody Techniques, Department of Cell Biology, Jiangsu Provincial Key Laboratory of Human Functional Genomics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu 211166, China; Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Institute for Brain Tumors, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 210029, China; The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu 214000, China; Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210009, China. Electronic address:
Glioblastoma is a highly aggressive primary brain tumor with glioblastoma stem cells (GSCs) enforcing the intra-tumoral hierarchy. Plasma cells (PCs) are critical effectors of the B-lineage immune system, but their roles in glioblastoma remain largely unexplored. Here, we leverage single-cell RNA and B cell receptor sequencing of tumor-infiltrating B-lineage cells and reveal that PCs are aberrantly enriched in the glioblastoma-infiltrating B-lineage population, experience low level of somatic hypermutation, and are associated with poor prognosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!